alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 251–275 of 522 studies in How common it is (page 11 of 21) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “How common it is” covers

How common it is — Counting patterns across whole populations: who gets dementia, at what age, and how that is changing.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2007-03-01

The plasma Abeta42/Abeta40 ratio may be a useful premorbid biomarker for identifying cognitively normal elderly white subjects who are at increased risk for developing MCI or AD. 5 key findings →

Participants: 53 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-01-01

Declines in heart disease and stroke mortality rates are conventionally attributed to reductions in cigarette smoking, recognition and treatment of hypertension and diabetes, effective medications to improve serum lipid levels and to reduce clot formation, and general lifestyle improvements. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

What the left and right anterior fusiform gyri tell us about semantic memory

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Brain : a journal of neurology 2010-10-15

The study of patients with semantic dementia, a variant of frontotemporal lobar degeneration, has emerged over the last two decades as an important lesion model for studying human semantic memory. 4 key findings →

Participants: 21 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Estrogen replacement therapy and risk of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of internal medicine 1996-10-01

This study suggests that estrogen replacement therapy may be useful for preventing or delaying the onset of Alzheimer disease in postmenopausal women. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prevalence of dementia in Singapore: Changes across a decade

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer s & Dementia 2025-01-27

The weighted prevalence of dementia based on the 10/66 Diagnostic Research Group (DRG) criteria was 8.8% (95% confidence interval [CI]: 7.3-10.7) in the WiSE 2023 study compared to 10% in the WiSE 2013 study (95% CI: 8.7-11.5). 5 key findings →

Design: cross-sectional Participants: 2,010 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Bariatric Surgery Is Associated With Reduced Incidence of Mild Cognitive Impairment and Alzheimer Disease and Related Dementias: A Retrospective Cohort Study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Annals of Surgery Open 2025-01-10

Bariatric surgery was associated with a significantly reduced incidence of ADRD, evidenced by a subdistribution hazard ratio (SHR) of 0.37 (95% confidence interval [CI]: 0.15–0.89; P = 0.03). 4 key findings →

Design: longitudinal study Participants: 5,303 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A multinational cohort study of trends in survival following dementia diagnosis

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Communications Medicine 2025-05-28

Data from 1,272,495 individuals, with the mean age at diagnosis ranging from 76.8 years (South Korea) to 82.9 years (Germany), show that the overall median length of survival following recorded diagnosis ranges from 2.4 years (New Zealand) to 7.9 years (South Korea). 2 key findings →

Design: cohort study Participants: 1,272,495 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence, incidence and modifiable factors for subtypes of mild cognitive impairment: results from the Longitudinal Ageing Study in China

✓ Peer-reviewed alzhub usefulness score 57 out of 100. General Psychiatry 2025-03-07

Among our participants, aMCI and VCIND demonstrated prevalence of 14.83% and 2.71%, respectively, and annual incidence (per 1000 person-years) of 69.6 and 10.6, respectively. 5 key findings →

Design: longitudinal study Participants: 2,051 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

✓ Peer-reviewed alzhub usefulness score 57 out of 100. American Journal of Public Health 1998-09-01

in 1997, the prevalence of Alzheimer's disease in the United States was 2.32 million (range: 1.09 to 4.58 million); of these individuals, 68% were female. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Bias in meta-analysis detected by a simple, graphical test

✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMJ 1997-09-13

A simple analysis of funnel plots provides a useful test for the likely presence of bias in meta-analyses, but as the capacity to detect bias will be limited when meta-analyses are based on a limited number of small trials the results from such analyses should be treated with considerable caution.

Full summary, score breakdown and related studies → Original source Free full text

Population attributable fractions of a wide range of peripheral diseases for the burden of dementia

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Nature human behaviour 2026-01-20

Growing evidence suggests that peripheral diseases serve as risk factors for dementia, but the population-level burden of dementia associated with various peripheral diseases has remained unknown. 3 key findings →

Design: meta-analysis Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Are memory complaints predictive for dementia? A review of clinical and population-based studies

✓ Peer-reviewed alzhub usefulness score 56 out of 100. International journal of geriatric psychiatry 2000-11-01

Memory complaints in elderly people should no longer be considered merely as an innocent age-related phenomenon or a symptom of depression. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of the American Medical Directors Association 2013-05-10

Using the OSHPE criteria, we found more participants with MCI than with frailty. 4 key findings →

Design: cross-sectional Participants: 5,104 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Basic characteristics and representativeness of the German Disease Analyzer database


✓ Peer-reviewed alzhub usefulness score 56 out of 100. International journal of clinical pharmacology and therapeutics 2018-10-01

There was a good agreement of the incidence or prevalence of major chronic diseases in the outpatient DA with German reference data. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer s Research & Therapy 2025-04-03

Plasma p-tau217 and p-tau231 were most effective in diagnosing aMCI/AD (AUC = 0.95 and 0.93, respectively), while p-tau217, p-tau231 and p-tau181 presented the best differential diagnosis for AD from PSP, FTD and DLB respectively (AUC = 0.84, 0.81 and 0.83). α-synuclein was presented as the best biomarker for PSP variant and behavior variant FTD subtypes (AUC = 0.81 and 0.74, respectively). 5 key findings →

Design: cross-sectional Participants: 668 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Long‐Term Incidence of Dementia Following Transient Ischemic Attack: A Longitudinal Cohort Study

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of the American Heart Association 2025-07-04

We found no significant difference in dementia incidence over a 20‐year follow‐up period compared with matched TIA‐free controls. 3 key findings →

Design: cohort study Participants: 297 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Associations of cardiometabolic multimorbidity with all-cause dementia, alzheimer’s disease, and vascular dementia: a cohort study in the UK biobank

✓ Peer-reviewed alzhub usefulness score 56 out of 100. BMC Public Health 2025-07-07

Compared with those without CMD, those with CMD multimorbidity had an elevated risk of ACD (hazard ratio [HR]: 2.27, 95% confidence interval [95% CI]: 1.95-2.63), AD (HR: 1.49, 95% CI: 1.13-1.97), and VD (HR: 3.70, 95% CI: 2.93-4.69). 5 key findings →

Design: cohort study Participants: 287,748 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed